The Library
A randomized trial of progesterone in women with bleeding in early pregnancy
Tools
Tools
Tools
(2019) A randomized trial of progesterone in women with bleeding in early pregnancy. New England Journal of Medicine, 380 (19). pp. 1815-1824. doi:10.1056/NEJMoa1813730
|
PDF
WRAP-randomised-trial-progesterone-women-bleeding-Quenby-2019.pdf - Published Version - Requires a PDF viewer. Download (829Kb) | Preview |
Official URL: http://dx.doi.org/10.1056/NEJMoa1813730
Abstract
BACKGROUND
Bleeding in early pregnancy is strongly associated with pregnancy loss. Progesterone is essential for the maintenance of pregnancy. Several small trials have suggested that progesterone therapy may improve pregnancy outcomes in women who have bleeding in early pregnancy.
METHODS
We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate progesterone, as compared with placebo, in women with vaginal bleeding in early pregnancy. Women were randomly assigned to receive vaginal suppositories containing either 400 mg of progesterone or matching placebo twice daily, from the time at which they presented with bleeding through 16 weeks of gestation. The primary outcome was the birth of a live-born baby after at least 34 weeks of gestation. The primary analysis was performed in all participants for whom data on the primary outcome were available. A sensitivity analysis of the primary outcome that included all the participants was performed with the use of multiple imputation to account for missing data.
RESULTS
A total of 4153 women, recruited at 48 hospitals in the United Kingdom, were randomly assigned to receive progesterone (2079 women) or placebo (2074 women). The percentage of women with available data for the primary outcome was 97% (4038 of 4153 women). The incidence of live births after at least 34 weeks of gestation was 75% (1513 of 2025 women) in the progesterone group and 72% (1459 of 2013 women) in the placebo group (relative rate, 1.03; 95% confidence interval [CI], 1.00 to 1.07; P=0.08). The sensitivity analysis, in which missing primary outcome data were imputed, resulted in a similar finding (relative rate, 1.03; 95% CI, 1.00 to 1.07; P=0.08). The incidence of adverse events did not differ significantly between the groups.
CONCLUSIONS
Among women with bleeding in early pregnancy, progesterone therapy administered during the first trimester did not result in a significantly higher incidence of live births than placebo. (Funded by the United Kingdom National Institute for Health Research Health Technology Assessment program; PRISM Current Controlled Trials number, ISRCTN14163439. opens in new tab.)
| Item Type: | Journal Article | ||||||
|---|---|---|---|---|---|---|---|
| Subjects: | Q Science > QP Physiology R Medicine > RG Gynecology and obstetrics |
||||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Cell & Developmental Biology Faculty of Medicine > Warwick Medical School > Biomedical Sciences Faculty of Medicine > Warwick Medical School |
||||||
| Library of Congress Subject Headings (LCSH): | Pregnancy -- Complications, Progesterone, Miscarriage -- Research | ||||||
| Journal or Publication Title: | New England Journal of Medicine | ||||||
| Publisher: | Massachussets Medical Society | ||||||
| ISSN: | 0028-4793 | ||||||
| Official Date: | 9 May 2019 | ||||||
| Dates: |
|
||||||
| Volume: | 380 | ||||||
| Number: | 19 | ||||||
| Page Range: | pp. 1815-1824 | ||||||
| DOI: | 10.1056/NEJMoa1813730 | ||||||
| Status: | Peer Reviewed | ||||||
| Publication Status: | Published | ||||||
| Access rights to Published version: | Restricted or Subscription Access | ||||||
| Copyright Holders: | Copyright © 2019, Massachusetts Medical Society | ||||||
| RIOXX Funder/Project Grant: |
|
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
